Skip to main content
  • Register
  • Help
  • Contact us

Norway extends AstraZeneca vaccination halt for another three weeks

Fri 26 March 2021 11:58 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Norway is set to delay its decision on whether to resume Covid-19 vaccinations with the AstraZeneca jab by another three weeks, the country's Institute of Public Health (FHI) said on Friday.

The vaccine was suspended on 11 March over fears that it was causing blood clots, bleeding and low platelet counts.

"We have decided to continue the pause and make a new decision by April 15," FHI chief Camilla Stoltenberg told broadcaster NRK.

"We have started several processes to map out whether there is a causality and to have a better basis to establish the real risk and a cost-benefit analysis for different age groups. To get more knowledge, it is necessary to have more time."

Norway is among many European countries to suspend the rollout of the vaccine over safety concerns. Some have since resumed its use following positive advice from the European Medicines Agency.

Norway currently uses the Pfizer/BioNTech and Moderna jabs and will be adding that from Johnson & Johnson once supplies become available in Europe.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More company news from ShareCast